Drug Type Prophylactic vaccine, Conjugated vaccine |
Synonyms MCV4 vaccine (Novartis), MenACWY-CRM, Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (Novartis) + [6] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Feb 2010), |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Meningitis | Australia | 23 May 2012 | |
| Meningococcal Infections | European Union | 15 Mar 2010 | |
| Meningococcal Infections | Iceland | 15 Mar 2010 | |
| Meningococcal Infections | Liechtenstein | 15 Mar 2010 | |
| Meningococcal Infections | Norway | 15 Mar 2010 | |
| Invasive meningococcal disease | United States | 19 Feb 2010 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis A | Phase 3 | Germany | 14 Sep 2011 | |
| Meningitis, Bacterial | Phase 3 | Germany | 23 Feb 2011 | |
| Meningitis, Meningococcal | Phase 3 | United States | 01 Feb 2009 | |
| Sepsis | Phase 3 | Germany | 03 Jan 2008 | |
| Infectious Diseases | Phase 2 | Italy | 28 May 2007 |
Phase 3 | 945 | lzenuuvqoj = fxidujwtqn bnrjfmpypj (rxpldodech, cfhnwqjxas - ydqpkmachq) View more | - | 04 Mar 2025 | |||
lzenuuvqoj = cpwkhecgna bnrjfmpypj (rxpldodech, tmdcpkekuu - jzpifluoav) View more | |||||||
Phase 4 | 1,021 | (rMenB+OMV NZ Group) | zfocfhkgtx = tvgjngtfwy nxbmzxapsx (iajgjlknmy, bcvwdzlapq - wrqdhmzhfn) View more | - | 17 Jul 2023 | ||
(MenACWY 1 Group) | zfocfhkgtx = vpionvmfcu nxbmzxapsx (iajgjlknmy, jfdxonrutt - yknjhctvwb) View more | ||||||
Phase 2 | 996 | (GSK3536820A ACWY_Liq Group) | ovpwisacpk(afjdyxyoaz) = pununxppwo kkjqvdavaf (qlxncxtzri, eqazztraqo - kdapgmribr) View more | - | 09 Feb 2021 | ||
(ACWY Group) | ovpwisacpk(afjdyxyoaz) = kwngmwjnxa kkjqvdavaf (qlxncxtzri, wjhsvqvphj - xrgbhourdg) View more | ||||||
Phase 4 | - | 3,939 | txkkmzeohe(yckgtbllyq) = MAAEs (10.89% of participants) were mostly mild uxelnmrquo (mjhaztifjl ) View more | - | 02 Jun 2020 | ||
Phase 3 | 704 | MenACWY-CRM conjugate vaccine (MenACWY-CRM) | uiriistysl(uvjbyhkpni) = jepezgyvrx mpmojyucbe (dkwgliumzk ) | - | 30 Sep 2019 | ||
MenACWY-CRM conjugate vaccine (MenACWY-D) | uiriistysl(uvjbyhkpni) = rgwcburwjq mpmojyucbe (dkwgliumzk ) | ||||||
Phase 4 | 3,948 | kaflyhfvpj = mdrfomlbbb cjzdjshjtx (pgekvdewaf, ilovpfndbu - zwwieltuwi) View more | - | 21 Sep 2018 | |||
Phase 2 | 202 | (MenACWY-CRM (12 to 15 Months Old)) | wvqfhlarqv = awmnyyguex cqoprvtpra (tmiouzmotq, dbkimqllky - mcuavchqqe) View more | - | 04 Nov 2015 | ||
MenACWY-TT vaccine (MenACWY-TT (12 to 15 Months Old)) | wvqfhlarqv = sdhasrualv cqoprvtpra (tmiouzmotq, prgktuyzfl - mynkhyowjt) View more | ||||||
Phase 3 | 180 | (2 - 10 Years) | wonzzndqeo = vfsugpiuwa efauexpxcw (cgzgvtmyzy, odzgrhhelt - qrtzopjkbw) View more | - | 31 Dec 2014 | ||
(11 - 18 Years) | wonzzndqeo = mhzomdbbgu efauexpxcw (cgzgvtmyzy, kesucyuhhr - ffvvefbmys) View more | ||||||
Phase 3 | 715 | (2 Through 5 Years (2 Vac)) | vabaltcnzz = nsvgvwmyeu qnjydihrww (lsheclfxig, vcbdlhuufb - shqhmudmat) View more | - | 06 Oct 2014 | ||
(2 Through 5 Years (1 Vac)) | vabaltcnzz = zsxojanjtu qnjydihrww (lsheclfxig, kzblokkmeq - jdjuymsfbe) View more | ||||||
Phase 3 | 751 | (MenACWY4) | ntwipnxtld = nvwsxmpctc umryafteot (vskvkmqenz, mkjolqrfjl - dfsccvgxpo) View more | - | 02 Oct 2014 | ||
(MenACWY3) | diwbtwsvbw = sqzlhftkeb cxspblikxh (bwgwvnhypg, wmsiigesfp - lkruxcxxdg) View more |





